PRTC

PureTech Health (PRTC)

PureTech Health PLC

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PRTC

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/23	20 : 00	Business Wire	PureTech to Present at the Jefferies Global Healthcare Conference	NASDAQ:PRTC	PureTech Health PLC
2024/05/21	20 : 05	Business Wire	PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection	NASDAQ:PRTC	PureTech Health PLC
2024/05/21	05 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PRTC	PureTech Health PLC
2024/05/20	20 : 03	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:PRTC	PureTech Health PLC
2024/05/20	15 : 00	Business Wire	PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share	NASDAQ:PRTC	PureTech Health PLC
2024/05/09	20 : 05	Business Wire	PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting	NASDAQ:PRTC	PureTech Health PLC
2024/05/07	20 : 05	Business Wire	PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments	NASDAQ:PRTC	PureTech Health PLC
2024/04/25	18 : 22	Business Wire	PureTech Announces Annual Results for Year Ended December 31, 2023	NASDAQ:PRTC	PureTech Health PLC
2024/04/18	15 : 00	Business Wire	PureTech Health: Notice of Results	NASDAQ:PRTC	PureTech Health PLC
2024/04/16	20 : 00	Business Wire	PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis	NASDAQ:PRTC	PureTech Health PLC
2024/04/11	20 : 00	Business Wire	PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers	NASDAQ:PRTC	PureTech Health PLC
2024/04/09	15 : 00	Business Wire	PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions	NASDAQ:PRTC	PureTech Health PLC
2024/03/19	16 : 00	Business Wire	PureTech Proposes $100 Million Capital Return	NASDAQ:PRTC	PureTech Health PLC
2024/03/18	22 : 52	Business Wire	Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion	NASDAQ:PRTC	PureTech Health PLC
2024/03/13	20 : 00	Business Wire	PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia	NASDAQ:PRTC	PureTech Health PLC
2024/02/27	21 : 00	Business Wire	PureTech to Present at Two Upcoming Investor Conferences	NASDAQ:PRTC	PureTech Health PLC
2024/02/27	16 : 00	Business Wire	PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan	NASDAQ:PRTC	PureTech Health PLC
2024/01/05	06 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PRTC	PureTech Health PLC
2024/01/03	21 : 00	Business Wire	PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:PRTC	PureTech Health PLC
2023/12/22	23 : 13	Business Wire	PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion	NASDAQ:PRTC	PureTech Health PLC
2023/12/20	16 : 00	Business Wire	PureTech Year End Update and Outlook for 2024	NASDAQ:PRTC	PureTech Health PLC
2023/12/07	20 : 00	Business Wire	PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023	NASDAQ:PRTC	PureTech Health PLC
2023/11/30	00 : 17	Business Wire	PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia	NASDAQ:PRTC	PureTech Health PLC
2023/11/17	16 : 00	Business Wire	PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia	NASDAQ:PRTC	PureTech Health PLC
2023/11/14	16 : 00	Business Wire	PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers	NASDAQ:PRTC	PureTech Health PLC
2023/11/03	05 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PRTC	PureTech Health PLC
2023/10/17	15 : 00	Business Wire	PureTech to Present at Two Upcoming Investor Conferences	NASDAQ:PRTC	PureTech Health PLC
2023/10/11	20 : 00	Business Wire	PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting	NASDAQ:PRTC	PureTech Health PLC
2023/10/04	20 : 05	Business Wire	PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation	NASDAQ:PRTC	PureTech Health PLC
2023/09/28	20 : 38	Business Wire	KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia	NASDAQ:PRTC	PureTech Health PLC